Bis(4-hydroxybutyl) benzene-1,2-dicarboxylate | 15818-56-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Bis(4-hydroxybutyl) benzene-1,2-dicarboxylate
• CAS: 15818-56-1
• 化学式: C₁₆H₂₂O₆
• 分子量: 310.34
• InChiKey: FUZUFZCLXLEROD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  93.1
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Therapeutic agent for overactive bladder involved in aging
  申请人：Yokoyama Osamu

  公开号：US20060135507A1

  公开（公告）日：2006-06-22

  A method for treating overactive bladder involved in aging, comprising administrating a compound having a cholinesterase inhibitory activity, a pharmacologically acceptable salt or a solvate thereof to a patient with the overactive bladder involved in aging.

  一种治疗老年人过度活跃膀胱的方法，包括向患有老年人过度活跃膀胱的患者施用具有胆碱酯酶抑制活性的化合物、药理学上可接受的盐或其溶剂。
• Therapeutic agent for overactive bladder resulting from cerebral infarction
  申请人：Yokoyama Osamu

  公开号：US20060172992A1

  公开（公告）日：2006-08-03

  An agent for treating overactive bladder resulting from cerebral infarction, comprising administrating a compound having a cholinesterase inhibitory activity or a pharmacologically acceptable salt thereof.

  一种用于治疗因脑梗死引起的过度活动膀胱的制剂，包括给予具有胆碱酯酶抑制活性或其药理学上可接受的盐的化合物。
• Aryl-substituted alicylic compound and medical composition comprising the same
  申请人：——

  公开号：US20040106622A1

  公开（公告）日：2004-06-03

  An aryl-substituted alicyclic compound of the formula (I): 1 wherein U is 1,4,5,6-tetrahydropyrimidin-2-yl, etc., A is phenylene, etc., B is piperidine-1,4-diyl, etc., Z is —CONH—, etc., R 3 is hydrogen, etc., R 5 is hydrogen, aryl, etc., R 6 is a mono-substituted amino (e,g., benzyloxycarbonylamino), R 7 is hydrogen, etc., and a process for preparation thereof, and a pharmaceutical composition containing the same. The compound of the present invention has a high selectivity for &agr;v&bgr;3 integrin, and exhibits a potent inhibitory activity thereto, and hence, it is useful as a preventive or/and a therapeutic agent for a disease in which &agr;v&bgr;3 integrin is involved.

  公式（I）的芳基取代脂环化合物：其中U为1,4,5,6-四氢嘧啶-2-基等，A为苯基等，B为哌啶-1,4-二基等，Z为—CONH—等，R3为氢等，R5为氢、芳基等，R6为单取代氨基（例如苄氧羰基氨基），R7为氢等。本发明还涉及一种制备该化合物的方法，以及含有该化合物的制药组合物。本发明化合物对αvβ3整合素有高度选择性，并表现出强大的抑制活性，因此，它可用作预防或治疗αvβ3整合素参与的疾病的药物。
• N-arylphenylacetamide derivatives and medicinal compositions containing the same
  申请人：——

  公开号：US20040248983A1

  公开（公告）日：2004-12-09

  N-Arylphenylacetamide derivatives represented by the following formula [I]: 1 (wherein R 1 is C 1-6 alkoxy, etc.; R 2 is hydrogen, —(CH 2 ) m —N(R 6 )(R 7 ) (m is an integer of from 1 to 4; R 6 is hydrogen, C 1-4 alkyl, etc., R 7 is hydrogen, etc.), etc.; R 3 is hydrogen, halogen, etc.; R 4 is C 6-10 alkyl, —Y—R 8 (Y is a single bond, C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, etc., R 8 is aryl, C 3-8 cycloalkyl, C 6-15 polycycloalkyl, etc.), etc.; R 5 is hydrogen, etc.; and X 1 is hydrogen), or pharmaceutically acceptable salts thereof or hydrates or solvates of the same, and a pharmaceutical composition containing the same. These compounds are useful as preventives and/or remedies giving no pain at the early stage of administration, which are efficacious in oral administration and have potent analgesic and antiinflammatory effects.

  下列式子所代表的N-Arylphenylacetamide衍生物[I]：1（其中R1是C1-6烷氧基等；R2是氢，-(CH2)m-N(R6)(R7)（m是从1到4的整数；R6是氢，C1-4烷基等，R7是氢等）等；R3是氢，卤素等；R4是C6-10烷基，-Y-R8（Y是单键，C1-6烷基，C2-6烯基，C2-6炔基等，R8是芳基，C3-8环烷基，C6-15多环烷基等）等；R5是氢等；X1是氢），或其药学上可接受的盐或其水合物或溶剂合物，以及含有它们的药物组成物。这些化合物在口服时具有强效的镇痛和抗炎作用，可用作早期给药时无痛的预防和/或治疗。
• 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
  申请人：Fujii Akihito

  公开号：US20050171196A1

  公开（公告）日：2005-08-04

  The present invention provides 2-furancarboxylic acid hydrazide compounds represented by General Formula (I) below, and prodrugs, physiologically acceptable salts, hydrates, solvates thereof, methods for producing them and pharmaceutical compositions containing them: wherein A is a group represented by Formula (a) or the like: (wherein either R 4 or R 5 represents cyano, nitro or the like, and the other represents a hydrogen atom or the like); either R 1 or R 2 represents a group: -D-(X)m-R 6 or the like, and the other represents a group: -E-(Y)n-R 7 , hydrogen atom, aryl or the like; R 3 is a hydrogen atom or the like; D and E independently represent aryl; X and Y independently represent O or the like; R 6 and R 7 independently represent alkyl, aryl, arylalkyl or the like; and m and n are independently 0 or 1, provided that the aryl is optionally substituted. Such compounds exhibit a potent antagonistic activity on glucagon receptor and are of use as preventive and/or therapeutic agents for symptoms and diseases in which glucagon is involved.

  本发明提供了由下列通式（I）表示的2-呋喃羧酸肼化合物，以及它们的前药、生理上可接受的盐、水合物、溶剂化物、制备方法和含有它们的制药组合物：其中A是由式（a）或类似式表示的基团：（其中R4或R5代表氰基、硝基或类似物，另一个代表氢原子或类似物）；R1或R2代表基团：-D-(X)m-R6或类似物，另一个代表基团：-E-(Y)n-R7、氢原子、芳基或类似物；R3是氢原子或类似物；D和E独立地表示芳基；X和Y独立地表示O或类似物；R6和R7独立地表示烷基、芳基、芳基烷基或类似物；m和n独立地表示0或1，但芳基可选择性地被取代。这些化合物表现出强大的胰高血糖素受体拮抗活性，并且可用作预防和/或治疗胰高血糖素参与的症状和疾病的药物。